APOE and Alzheimer disease: There was a greater proportion of APOE-4 carriers in the patient group (n = 60/48%) compared with controls (n = 12/20%), and the opposite was true for APOE-4 noncarriers (AD: n = 65/52%; HC: n = 48/80%).